Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
Argenx takes a step towards convenience
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.
Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
